BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Zymeworks readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Zymeworks's drugs run\, from Clin
 icalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06695845-2201@assetmemo.bio
DTSTAMP:20261121T003818Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT06695845)
DESCRIPTION:Zanidatamab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A P
 hase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/zanidatamab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06695845
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07102381-2201@assetmemo.bio
DTSTAMP:20261121T003818Z
DTSTART;VALUE=DATE:20271229
DTEND;VALUE=DATE:20271230
SUMMARY:Zanidatamab: Phase 2 readout est. (NCT07102381)
DESCRIPTION:Zanidatamab\, phase 2\, HER2-Positive Breast Cancer.\nStudy: A 
 Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy 
 in Participants With HER2-positive Breast Cancer\nEstimated primary comple
 tion: 29 December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/zanidatamab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07102381
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06435429-2201@assetmemo.bio
DTSTAMP:20261121T003818Z
DTSTART;VALUE=DATE:20280428
DTEND;VALUE=DATE:20280429
SUMMARY:Zanidatamab: Phase 3 readout est. (NCT06435429)
DESCRIPTION:Zanidatamab\, phase 3\, HER2-Positive Breast Cancer.\nStudy: A 
 Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab\, Ea
 ch in Combination With Physician's Choice Chemotherapy\, for the Treatment
  of Participants With Metastatic HER2-positive Breast Cancer\nEstimated pr
 imary completion: 28 April 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/zanidatamab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06435429
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06282575-2201@assetmemo.bio
DTSTAMP:20261121T003818Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Zanidatamab: Phase 3 readout est. (NCT06282575)
DESCRIPTION:Zanidatamab\, phase 3\, Biliary Tract Cancer.\nStudy: Efficacy 
 and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-o
 f-care Therapy for Advanced HER2-positive Biliary Tract Cancer\nEstimated 
 primary completion: 1 December 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/zanidatamab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06282575
URL:https://assetmemo.bio/drug/zanidatamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
